CN107050107A - A kind of composition of medicine for coordinating treatment hypertension - Google Patents
A kind of composition of medicine for coordinating treatment hypertension Download PDFInfo
- Publication number
- CN107050107A CN107050107A CN201611245849.0A CN201611245849A CN107050107A CN 107050107 A CN107050107 A CN 107050107A CN 201611245849 A CN201611245849 A CN 201611245849A CN 107050107 A CN107050107 A CN 107050107A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- subassembly
- hypertension
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
Abstract
The invention discloses a kind of composition of medicine for coordinating treatment hypertension, including following parts by weight into subassembly：Into subassembly A：The combination of multivitamin and trace element；Into subassembly B：The combination of calcium and magnesium；Into subassembly C：The red sage root, pseudo-ginseng and borneol；Into subassembly D：EPA, DHA and vitamin E.Mentioned component is constituted, comprehensive adjustment metabolic disorder, recovery blood vessel elasticity, the reduction various functions such as high blood pressure and complication, it can reach the purpose of Synergistic, fundamentally coordinate Hypertension disease, the patient of 60 ~ 70% essential hypertensions can be effected a radical cure, reduce or do not occur hypertension complication, significantly reduce the financial burden of hyperpietic, be that society brings up bigger welfare.
Description
Technical field
The present invention relates to pharmaceutical field, more particularly to a kind of composition of medicine for coordinating treatment hypertension.
Background technology
Hypertension（hypertension）Refer to systemic arterial blood pressure（Systolic pressure and/or diastolic pressure）Increase to be main
Feature（The millimetres of mercury of systolic pressure >=140, the millimetres of mercury of diastolic pressure >=90）, can with the organs such as the heart, brain, kidney function or device matter
Property infringement clinical syndrome.Hypertension is most common chronic disease, is also the topmost hazards of cardiovascular and cerebrovascular diseases.High blood
The basic reason that pressure disease is produced, is due to that various factors acts on body, causes the various metabolic disorders of body, cause blood viscosity to increase
High, blood fat increases, vascular atherosclerosis, vascular lesion, and then causes the generation of hypertension and complication.
The intervening measure of the hypertension proposed at present, the mark not refined specifically and way, it is impossible to formed
Unified standard.So simple have certain effect in terms of custom of making the life better, can not very effective intervention hypertension
Generation or radical cure hypertension.And current antihypertensive drugs controls hypertension simply by blood volume and expansion blood vessel is reduced.
This method can only control hypertension, but it is cured the symptoms, not the disease, can not be from causing the basic reason of hypertension to effect a radical cure high
Blood pressure, so, all the time, hypertension is treated as a chronic disease, even if hyperpietic and doctor coordinate control
Cardiovascular hazards are made, may can only also delay the generation of complication, but can not fundamentally solve cardiovascular
Complication.Above mentioned problem generates skew mainly due to traditional medicine to high blood pressure understanding, therefore at present to hypertension
Research is primarily directed to the research for how controlling hypertension He slowing down or control complication, not from the cause of disease for producing hypertension
Or mechanism expansion research.
The content of the invention
The invention provides a kind of composition of medicine for coordinating treatment hypertension, the cause of disease and mechanism produced from research hypertension
Angle is set out, and by intervening and treating the cause of disease, cooperates with hypertension drug to effect a radical cure hypertension.
To achieve the above object, the technical scheme is that：
A kind of composition of medicine for coordinating treatment hypertension, including following parts by weight into subassembly：
Into subassembly A：0.25 ~ 0.40 part of vitamin A, 200 ~ 300 parts of vitamin C, 0.002 ~ 0.005 part of vitamin D, dimension
Raw 2000 ~ 3000 parts of element E, 5 ~ 6 parts of vitamin B1,5 ~ 6 parts of vitamin B2,5 ~ 6 parts of vitamin B6, vitamin B12
0.001 ~ 0.005 part, 0.1 ~ 0.2 part of folic acid, 10 ~ 13 parts of nicotinic acid, 8 ~ 10.5 parts of pantothenic acid, 0.06 ~ 0.1 part of biotin, calcium 250
~ 350 parts, 10 ~ 150 parts of magnesium, 0.001 ~ 0.008 part of selenium, 0.01 ~ 0.02 part of chromium, 1.5 ~ 2.5 parts of manganese, 0.5 ~ 0.8 part of copper, iron
2 ~ 3 parts, 7 ~ 9 parts of zinc, 15 ~ 22 parts of inositol；
Into subassembly B：600 ~ 670 parts of calcium, 250 ~ 330 parts of magnesium；
Into subassembly C：1200 ~ 1900 parts of the red sage root, 400 ~ 570 parts of pseudo-ginseng, 22 ~ 33 parts of borneol;
Into subassembly D：300 ~ 400 parts of EPA, 200 ~ 260 parts of DHA, 30 ~ 50 parts of vitamin E.
The above-described composition of medicine for coordinating treatment hypertension, preferably include following parts by weight into subassembly：
Into subassembly A：0.38 part of vitamin A, 225 parts of vitamin C, 0.004 part of vitamin D, 2250 parts of vitamin E, dimension
Raw 5.5 parts of element B1,5.5 parts of vitamin B2,5.5 parts of vitamin B6,0.004 part of vitamin B12,0.15 part of folic acid, cigarette
12.5 parts of acid, 10 parts of pantothenic acid, 0.09 part of biotin, 300 parts of calcium, 150 parts of magnesium, 0.006 part of selenium, 0.018 part of chromium, 2 parts of manganese, copper
0.75 part, 2.15 parts of iron, 7.5 parts of zinc, 20 parts of inositol；
Into subassembly B：650 parts of calcium, 325 parts of magnesium；
Into subassembly C：1800 parts of the red sage root, 560 parts of pseudo-ginseng, 32 parts of borneol；
Into subassembly D：360 parts of EPA, 240 parts of DHA, 40 parts of vitamin E.
Coordination treatment weight is being prepared invention further provides the above-described composition of medicine for coordinating treatment hypertension
Degree or application during moderate hypertension Patient drug.Severe hypertension patient refers to the millimetres of mercury of systolic pressure >=180, diastolic pressure >=
110 millimetress of mercury, moderate hypertension patient refers to that systolic pressure is 160 ~ 179 millimetress of mercury, and diastolic pressure is 100 ~ 109 millimeters of mercury
Post.
In addition, present invention also offers a kind of composition of medicine for coordinating treatment hypertension, including the composition of following parts by weight
Combination：
Into subassembly E：0.25 ~ 0.40 part of vitamin A, 200 ~ 300 parts of vitamin C, 0.002 ~ 0.005 part of vitamin D, dimension
Raw 2000 ~ 3000 parts of element E, 5 ~ 6 parts of vitamin B1,5 ~ 6 parts of vitamin B2,5 ~ 6 parts of vitamin B6, vitamin B12
0.001 ~ 0.005 part, 0.1 ~ 0.2 part of folic acid, 10 ~ 13 parts of nicotinic acid, 8 ~ 10.5 parts of pantothenic acid, 0.06 ~ 0.1 part of biotin, calcium 250
~ 350 parts, 10 ~ 150 parts of magnesium, 0.001 ~ 0.008 part of selenium, 0.01 ~ 0.02 part of chromium, 1.5 ~ 2.5 parts of manganese, 0.5 ~ 0.8 part of copper, iron
2 ~ 3 parts, 7 ~ 9 parts of zinc, 15 ~ 22 parts of inositol；
Into subassembly F：200 ~ 220 parts of calcium, 50 ~ 110 parts of magnesium；
Into subassembly G：1100 ~ 1450 parts of the red sage root, 380 ~ 430 parts of pseudo-ginseng, 20 ~ 25 parts of borneol；
Into subassembly H：180 ~ 360 parts of EPA, 120 ~ 240 parts of DHA, 20 ~ 40 parts of vitamin E.
The above-described composition of medicine for coordinating treatment hypertension, preferably include following parts by weight into subassembly：
Into subassembly E：0.38 part of vitamin A, 225 parts of vitamin C, 0.004 part of vitamin D, 2250 parts of vitamin E, dimension
Raw 5.5 parts of element B1,5.5 parts of vitamin B2,5.5 parts of vitamin B6,0.004 part of vitamin B12,0.15 part of folic acid, cigarette
12.5 parts of acid, 10 parts of pantothenic acid, 0.09 part of biotin, 300 parts of calcium, 150 parts of magnesium, 0.006 part of selenium, 0.018 part of chromium, 2 parts of manganese, copper
0.75 part, 2.15 parts of iron, 7.5 parts of zinc, 20 parts of inositol；
Into subassembly F：216.7 parts of calcium, 108.3 parts of magnesium；
Into subassembly G：1350 parts of the red sage root, 420 parts of pseudo-ginseng, 24 parts of borneol；
Into subassembly H：EPA180 parts, 120 parts of DHA, 20 parts of vitamin E.
Coordinate to treat light in preparation invention further provides the above-described composition of medicine for coordinating treatment hypertension
Spend application during hyperpietic's medicine.Mild hypertension refers to that systolic pressure is 140 ~ 159 millimetress of mercury, and diastolic pressure is 90
~ 99 millimetress of mercury.
The above-described composition of medicine for coordinating treatment hypertension, including two kinds of combinations, this two kinds are combined as a series
Composition of medicine, separately designed for severe hypertension patient and mild hyperpietic, its mechanism of action is：Coordinate each in vivo
Metabolism is planted, gradually recovers eubolism, expansion blood vessel and softening blood vessel, reduction blood viscosity.Wherein, respectively into the work of subassembly
With for：
（1）Into subassembly A and into subassembly E：There is provided various basic vitamins, mineral matter and trace element for body, promote and
Recover normal body metabolism, and then reduce internal blood fat, blood glucose and reduce blood viscosity, while internal rubbish is removed,
This is the morbidity source i.e. angle of metabolic disorder from hypertension, effects a radical cure the cause of disease of hypertension, is not sent out even so as to reduce
The complication of raw hypertension.
（2）Into subassembly B and into subassembly F：Calcium and magnesium play the role of expansion blood vessel, reduced blood pressure, while can be with soft
Change blood vessel hardness, so that blood vessel gradually recovers normal elasticity.
（3）Into subassembly C and into subassembly G：Red sage root stasis-dispelling and pain-killing, blood circulation promoting nourishes blood, relieving restlessness that clears away heart-fire is main ingredient, is aided with pseudo-ginseng
Blood circulation and channel invigorating, blood-activating analgetic is helped with borneol resuscitation with aromatics, promoting qi circulation and relieving pain, all medicine phases are matched somebody with somebody, with promoting blood circulation and removing blood stasis, resuscitation with aromatics, reason
The work(of gas analgesic, can dredging vascellum, reduce cardiovascular complication generation, be conducive to the rehabilitation of high blood pressure and complication.
（4）Into subassembly D and into subassembly H：EPA, i.e. eicosapentaenoic acid english abbreviation, are OMEGA-3 with DHA
(Omega 3) aliphatic acid, the function with regulation blood fat, moreover it is possible to reduce cholesterol in blood plasma, triglycerides, low-density lipoprotein
In vain, VLDL, increase HDL.
Mentioned component is constituted, and comprehensive adjustment metabolic disorder, recovery blood vessel elasticity, reduction high blood pressure and complication etc. are many
Function, can reach the purpose of Synergistic, fundamentally coordinates Hypertension disease, can effect a radical cure 60 ~ 70% essential hypertensions
Patient, reduce or do not occur hypertension complication, significantly reduce the financial burden of hyperpietic, be society bring up it is bigger
Welfare.
Embodiment
Below in conjunction with specific embodiment, the invention will be further described, but protection scope of the present invention be not limited to it is following
Embodiment.
Embodiment 1
A kind of composition of medicine for coordinating treatment hypertension, including following weight mg into subassembly：
Into subassembly A：Vitamin A 0.25mg, vitamin C 200mg, vitamin D 0.002mg, vitamin E 2g, vitamin
B1 5mg, vitamin B2 5mg, vitamin B6 5mg, vitamin B12 0.001mg, folic acid 0.1mg, nicotinic acid 10mg, pantothenic acid
8mg, biotin 0.06mg, calcium 250mg, magnesium 10mg, selenium 0.001mg, chromium 0.01mg, manganese 1.5mg, copper 0.5mg, iron 2mg,
Zinc 7mg, inositol 15mg；
Into subassembly B：Calcium 600mg, magnesium 290mg；
Into subassembly C：Red sage root 1.2g, pseudo-ginseng 400mg, borneol 22mg;
Into subassembly D：200 mg of mg, DHA of EPA 300, the mg of vitamin E 30.
Embodiment 2
A kind of composition of medicine for coordinating treatment hypertension, including following weight mg into subassembly：
Into subassembly A：Vitamin A 0.38mg, vitamin C 225mg, vitamin D 0.004mg, vitamin E 2.25g, dimension life
Plain B1 5.5mg, vitamin B2 5.5mg, vitamin B6 5.5mg, vitamin B12 0.004mg, the mg of folic acid 0.15, nicotinic acid
12.5mg, pantothenic acid 10mg, biotin 0.09mg, calcium 300mg, magnesium 150mg, selenium 0.006mg, chromium 0.018mg, manganese 2mg, copper
0.75mg, iron 2.15mg, zinc 7.5mg, inositol 20mg；
Into subassembly B：Calcium 650mg, magnesium 325mg；
Into subassembly C：Red sage root 1.8g, pseudo-ginseng 560mg, borneol 32mg;
Into subassembly D：240 mg of mg, DHA of EPA 360, the mg of vitamin E 40.
Embodiment 3
A kind of composition of medicine for coordinating treatment hypertension, including following weight mg into subassembly：
Into subassembly A：Vitamin A 0.4mg, vitamin C 300mg, vitamin D 0.005mg, vitamin E 3g, vitamin B1
6mg, vitamin B2 6mg, vitamin B6 6mg, vitamin B12 0.005mg, folic acid 0.2mg, nicotinic acid 13mg, pantothenic acid
10.5mg, biotin 0.1mg, calcium 350mg, magnesium 150mg, selenium 0.008mg, chromium 0.02mg, manganese 2.5mg, copper 0.8mg,
Iron 3mg, zinc 9mg, inositol 22mg；
Into subassembly B：Calcium 670mg, magnesium 250mg；
Into subassembly C：Red sage root 1.9g, pseudo-ginseng 570mg, borneol 33mg;
Into subassembly D：260 mg of mg, DHA of EPA 400, the mg of vitamin E 50.
Embodiment 4
A kind of composition of medicine for coordinating treatment hypertension, including following weight mg into subassembly：
Into subassembly E：Vitamin A 0.25mg, vitamin C 200mg, vitamin D 0.002mg, vitamin E 2g, vitamin
B1 5mg, vitamin B2 5mg, vitamin B6 5mg, vitamin B12 0.001mg, folic acid 0.1mg, nicotinic acid 10mg, pantothenic acid
8mg, biotin 0.06mg, calcium 250mg, magnesium 10mg, selenium 0.001mg, chromium 0.01mg, manganese 1.5mg, copper 0.5mg, iron
2mg, zinc 7mg, inositol 15mg；
Into subassembly F：Calcium 200mg, magnesium 50mg；
Into subassembly G：Red sage root 1.1g, pseudo-ginseng 380mg, borneol 20mg;
Into subassembly H：120 mg of mg, DHA of EPA 180, the mg of vitamin E 20.
Embodiment 5
A kind of composition of medicine for coordinating treatment hypertension, including following weight mg into subassembly：
Into subassembly D：Vitamin A 0.38mg, vitamin C 225mg, vitamin D 0.004mg, vitamin E 2.25g, dimension life
Plain B1 5.5mg, vitamin B2 5.5mg, vitamin B6 5.5mg, vitamin B12 0.004mg, the mg of folic acid 0.15, nicotinic acid
12.5mg, pantothenic acid 10mg, biotin 0.09mg, calcium 300mg, magnesium 150mg, selenium 0.006mg, chromium 0.018mg, manganese 2mg, copper
0.75mg, iron 2.15mg, zinc 7.5mg, inositol 20mg；
Into subassembly E：Calcium 216.7mg, magnesium 108.3mg；
Into subassembly F：Red sage root 1.35g, pseudo-ginseng 420mg, borneol 24mg;
Into subassembly H：EPA180 mg, DHA 120 mg, the mg of vitamin E 20.
Embodiment 6
A kind of composition of medicine for coordinating treatment hypertension, including following weight mg into subassembly：
Into subassembly E：Vitamin A 0.4mg, vitamin C 300mg, vitamin D 0.005mg, vitamin E 3g, vitamin B1
6mg, vitamin B2 6mg, vitamin B6 6mg, vitamin B12 0.005mg, folic acid 0.2mg, nicotinic acid 13mg, pantothenic acid
10.5mg, biotin 0.1mg, calcium 350mg, magnesium 150mg, selenium 0.008mg, chromium 0.02mg, manganese 2.5mg, copper 0.8mg,
Iron 3mg, zinc 9mg, inositol 22mg；
Into subassembly F：Calcium 220mg, magnesium 110mg；
Into subassembly G：Red sage root 1.45g, pseudo-ginseng 430mg, borneol 25mg；
Into subassembly H：EPA360 mg, DHA 240mg, the mg of vitamin E 40.
Embodiment 7
A kind of composition of medicine for coordinating treatment hypertension, including following weight mg into subassembly：
Into subassembly E：Vitamin A 0.38mg, vitamin C 225mg, vitamin D 0.004mg, vitamin E 2.25g, dimension life
Plain B1 5.5mg, vitamin B2 5.5mg, vitamin B6 5.5mg, vitamin B12 0.004mg, the mg of folic acid 0.15, nicotinic acid
12.5mg, pantothenic acid 10mg, biotin 0.09mg, calcium 300mg, magnesium 150mg, selenium 0.006mg, chromium 0.018mg, manganese 2mg, copper
0.75mg, iron 2.15mg, zinc 7.5mg, inositol 20mg；
Into subassembly F：Calcium 216.7mg, magnesium 108.3mg；
Into subassembly G：Red sage root 1.35g, pseudo-ginseng 420mg, borneol 24mg;
Into subassembly H：EPA360 mg, DHA 240mg, the mg of vitamin E 40.
Application Example 1
1st, tablet is made in the medicine of above-described embodiment 2 and embodiment 4, wherein, 1 is made into subassembly A, into subassembly B systems
Into 3, it is made 12 into subassembly C, is made 2 into subassembly D；1 is made into subassembly E, 1 is made into subassembly F, into
Subassembly G is made 9, and 1 is made into subassembly H.Said medicine is used for the treatment of severe hypertension patient 120, wherein,
Treatment group：60, it is divided into four-stage treatment：A. early stage coordinates hypertension drug to use：Nifedipine sustained release tablets 10mg, daily
2 times, triamterene hydrochlorothiazide tablets, 2 times a day, and 1 tablet once, and take into subassembly A, one time a day, 1 tablet once, into packet
Close B, 3 times a day, 1 tablet once, into subassembly C, 3 times a day, 4 tablets once, and into subassembly D, 2 times a day, 1 tablet once；B. treat
When switching to moderate hypertension patient, hypertension drug is coordinated to use：Nifedipine sustained release tablets 10mg, 2 times a day, triamterene hydrogen
Chlorothiazide piece, 2 times a day, and 1 tablet once, but gradually reduces consumption, and take into subassembly A, one time a day, 1 tablet once, composition
Combine B, 3 times a day, 1 tablet once, into subassembly C, 3 times a day, 4 tablets once, and into subassembly D, 2 times a day, 1 tablet once；c.
When the previous moon of mild hypertension is switched to, subassembly E is taken into, one time a day, 1 tablet once, into subassembly F, daily
1 time, 1 tablet once, into subassembly G, 3 times a day, 3 tablets once, and into subassembly H, 2 times a day, 1 tablet once；D.1 after individual month, clothes
With into subassembly E, one time a day, 1 tablet once, into subassembly F, one time a day, 1 tablet once, into subassembly G, 3 times a day, every time 3
Piece, into subassembly H, one time a day, 1 tablet once, and c, d phase treatment time are 3 months.Control group：60, according to usage and dosage
Nifedipine sustained release tablets 10mg is taken, 2 times a day, triamterene hydrochlorothiazide tablets, 2 times a day, and 1 tablet once.
2nd, case selection standard：
A. primary hypertension patient.
B. normal renal function.
C. can partner treatment, the patient of further consultation on time.
3rd, criterion of therapeutical effect：
A. cure：In the case where stopping associated hypertension drug therapy, blood pressure, which can voluntarily adjust blood pressure by body, makes blood pressure
Recover normal, daily blood pressure is in below 140/90mmHg, and long-time（6 months）Remain stable, referred to as hypertension is cured.
B. it is effective：On the basis of drug therapy, hypertension symptom disappears substantially, and controlling of blood pressure is stable, high in 6 months
Blood pressure recurrence has hypertension recurrence less than 6 times or occasionally（It is less than 2 times in 1 month）.
C. it is effective：On the basis of drug therapy, with not treating preceding ratio, hypertension symptom mitigates, drop in blood pressure, but often
There is fluctuation of blood pressure.
D. it is invalid：Hypertension symptom is not improved, and blood pressure is without obvious change（Change is no more than 20% or high drops not
More than 30mmHg）.
4th, result of the test see the table below：
| Group | Cure | Cure rate（%） | It is effective | Obvious effective rate（%） | Effectively | It is efficient（%） | It is invalid | Inefficiency（%） |
| Treatment group | 42 | 70 | 17 | 28.3 | 1 | 1.7 | 0 | 0 |
| Control group | 2 | 3.3 | 20 | 33.3 | 35 | 58.4 | 3 | 5 |
5th, model case
It is recommended that enumerating the treatment of some typical patients, such as：
Case 1：Lee, female, 60 years old.Main suit：Headache, alliteration 1 month, are aggravated 3 days.Medical history：Without bright before patient's private prosecution one month
There is discontinuity headache, dizzy, activity postemphasis in aobvious inducement, with insomnia, without uncomfortable in chest, pectoralgia, no nausea and vomiting, without height of shivering
Heat, the symptom such as unparalleled edema of lower extremity.Through measuring maximal blood pressure 230/135mmHg.
Past medical history：Patient previously has systemic loupus erythematosus syndrome, lupus cerebritis, lupus nephritis, long-term taking
Prednisone acetate tablets（4,1 times/day, first take 15 years）Treatment, often occur subcutaneous hemorrhage, faint, eyes amaurosis, stomach and intestine
The complication such as road disorder.Previously without hypertension, coronary heart disease, diabetes chronic diseases history, no Family history of cancer.
After treating as stated above, through a phase treatments 10 days, fluctuation of blood pressure was between 180-140/110-90mmHg；Through b
Phase treatment 20 days, and blood-pressure drug is gradually decreased, fluctuation of blood pressure is between 165-140/103-90mmHg；Through c, d stage
Treatment 3 months, blood pressure is never raised, and never occurs headache and dizzy and insomnia again, does not occur other complication, and physical recovery is good for
Health.
Case 2：Tan, man, 58 years old.Main suit：Headache, 1 first quarter moon of alliteration.Medical history：Without substantially before patient's private prosecution one month
There is discontinuity headache, dizzy, activity postemphasis in inducement, with insomnia, without uncomfortable in chest, pectoralgia, no nausea and vomiting, without height of shivering
Heat, the symptom such as unparalleled edema of lower extremity.Through measuring maximal blood pressure 220/130mmHg.
After treating as stated above, through a phase treatments 7 days, fluctuation of blood pressure was between 180-140/110-90mmHg；Through b
Phase treatment 18 days, and blood-pressure drug is gradually decreased, fluctuation of blood pressure is between 165-140/103-90mmHg；Through c, d stage
Treatment 3 months, blood pressure is never raised, and never occurs headache and dizzy and insomnia again, does not occur other complication, and physical recovery is good for
Health.
Brief summary：High blood pressure is a chronic treatment, and the main flow direction treated at present is to need long-term taking antihypertensive drugs
Treatment maintains blood pressure stabilization.Medicine includes angiotensin converting enzyme inhibitor, Angiotensin Ⅱ receptor antagonist, beta-receptor
Retarding agent, calcium antagonist, diuretics.Its Treatment of Hypertension dominant mechanism is：Expand blood vessel, blood volume reduced, so as to reach one
The purpose of decompression, but above-mentioned treatment method, the reason for fundamentally can not solving high blood pressure, simply symptomatic treatment, does not have
The basic reason for causing hypertension is treated.High blood pressure is a performance of high blood pressure, rather than causes hypertension
The basic reason of disease, all simple Treatment of Hypertension can not effect a radical cure hypertension, can not prevent the generation of complication.Simply
Say, though high blood pressure controlling of blood pressure in below 140/90mmHg, the complication of high blood pressure still carrying out in concealment,
Here it is the reason for high blood pressure can not be effected a radical cure for a long time at present.
Cause the factor of hyperpiesia a lot, including：1st, inherent cause；2nd, spirit and environmental factor；3、
Age factor；4th, habits and customs factor；5th, the influence of medicine；6th, the influence of other diseases.Applicant of the present invention draws through analysis
Exception or lesion occur for the basic reason or body for playing hyperpiesia, and age, spirit and environment etc. is wherein
Fuse cord.Further analyze, cause body to occur the factor of exception or lesion, infer the basic original of high blood pressure
It is disorderly because being likely to be body metabolism, cause metabolic disorder, occur blood viscosity increase, blood fat rise, vascular sclerosis, artery it is athero-
The complication such as hardening, Vascular aberration, and then it is abnormal to show as kidney minute lesion, aberrant angiogenesis, blood dyscrasia, cardiac function,
Blood pressure rise is eventually exhibited as, and simply abnormal presentation occurs for a body for blood pressure rise.Therefore, hypertension radical-ability
Treatment, according to above-mentioned analysis and clinical trial, it should treated in terms of organism metabolism, makes physical recovery eubolism,
The reason for releasing hypertension from root, allows body oneself to adjust, and recovers normal arterial pressure.
The present invention is by supplementing multivitamin（Including multivitamin, trace element, mineral matter etc.）, unsaturated fat
Acid, while also can suitably supplement appropriate protein（Necessary amino acid in added body）, organism metabolism is adjusted, makes physical recovery
Eubolism, so that blood fat, reduction blood viscosity etc. are reduced, so as to release the internal factor for causing high blood pressure.And supplement calcium
Magnesium sheet, then be slowly to be depressured using the antihypertensive effect of calcium and magnesium piece, it is to avoid the fluctuation of blood pressure.The compounding of the red sage root, pseudo-ginseng and borneol, then
Play the role of promoting blood circulation and removing blood stasis, it is possible to reduce complication caused by hypertension.The combination of said medicine, can adjust organism metabolism,
Make physical recovery eubolism, while making angiomalasia, gradually recover blood vessel elasticity, so as to solve the vascular factor of hypertension.
Clinical tests prove that, the probability for curing high blood pressure reaches 70%, and can reduce or preventing hypertension disease complication generation.
Claims (6)
1. a kind of composition of medicine for coordinating treatment hypertension, it is characterised in that：
Including following parts by weight into subassembly：
Into subassembly A：0.25 ~ 0.40 part of vitamin A, 200 ~ 300 parts of vitamin C, 0.002 ~ 0.005 part of vitamin D, dimension
Raw 2000 ~ 3000 parts of element E, 5 ~ 6 parts of vitamin B1,5 ~ 6 parts of vitamin B2,5 ~ 6 parts of vitamin B6, vitamin B12
0.001 ~ 0.005 part, 0.1 ~ 0.2 part of folic acid, 10 ~ 13 parts of nicotinic acid, 8 ~ 10.5 parts of pantothenic acid, 0.06 ~ 0.1 part of biotin, calcium 250
~ 350 parts, 10 ~ 150 parts of magnesium, 0.001 ~ 0.008 part of selenium, 0.01 ~ 0.02 part of chromium, 1.5 ~ 2.5 parts of manganese, 0.5 ~ 0.8 part of copper, iron
2 ~ 3 parts, 7 ~ 9 parts of zinc, 15 ~ 22 parts of inositol；
Into subassembly B：600 ~ 670 parts of calcium, 250 ~ 330 parts of magnesium；
Into subassembly C：1200 ~ 1900 parts of the red sage root, 400 ~ 570 parts of pseudo-ginseng, 22 ~ 33 parts of borneol;
Into subassembly D：300 ~ 400 parts of EPA, 200 ~ 260 parts of DHA, 30 ~ 50 parts of vitamin E.
2. the composition of medicine according to claim 1 for coordinating treatment hypertension, it is characterised in that：
Including following parts by weight into subassembly：
Into subassembly A：0.38 part of vitamin A, 225 parts of vitamin C, 0.004 part of vitamin D, 2250 parts of vitamin E, dimension
Raw 5.5 parts of element B1,5.5 parts of vitamin B2,5.5 parts of vitamin B6,0.004 part of vitamin B12,0.15 part of folic acid, cigarette
12.5 parts of acid, 10 parts of pantothenic acid, 0.09 part of biotin, 300 parts of calcium, 150 parts of magnesium, 0.006 part of selenium, 0.018 part of chromium, 2 parts of manganese, copper
0.75 part, 2.15 parts of iron, 7.5 parts of zinc, 20 parts of inositol；
Into subassembly B：650 parts of calcium, 325 parts of magnesium；
Into subassembly C：1800 parts of the red sage root, 560 parts of pseudo-ginseng, 32 parts of borneol；
Into subassembly D：360 parts of EPA, 240 parts of DHA, 40 parts of vitamin E.
3. the composition of medicine as claimed in claim 1 or 2 for coordinating treatment hypertension coordinates treatment severe in preparation or moderate is high
Application during blood pressure Patient drug.
4. a kind of composition of medicine for coordinating treatment hypertension, it is characterised in that：
Including following parts by weight into subassembly：
Into subassembly E：0.25 ~ 0.40 part of vitamin A, 200 ~ 300 parts of vitamin C, 0.002 ~ 0.005 part of vitamin D, dimension
Raw 2000 ~ 3000 parts of element E, 5 ~ 6 parts of vitamin B1,5 ~ 6 parts of vitamin B2,5 ~ 6 parts of vitamin B6, vitamin B12
0.001 ~ 0.005 part, 0.1 ~ 0.2 part of folic acid, 10 ~ 13 parts of nicotinic acid, 8 ~ 10.5 parts of pantothenic acid, 0.06 ~ 0.1 part of biotin, calcium 250
~ 350 parts, 10 ~ 150 parts of magnesium, 0.001 ~ 0.008 part of selenium, 0.01 ~ 0.02 part of chromium, 1.5 ~ 2.5 parts of manganese, 0.5 ~ 0.8 part of copper, iron
2 ~ 3 parts, 7 ~ 9 parts of zinc, 15 ~ 22 parts of inositol；
Into subassembly F：200 ~ 220 parts of calcium, 50 ~ 110 parts of magnesium；
Into subassembly G：1100 ~ 1450 parts of the red sage root, 380 ~ 430 parts of pseudo-ginseng, 20 ~ 25 parts of borneol；
Into subassembly H：180 ~ 360 parts of EPA, 120 ~ 240 parts of DHA, 20 ~ 40 parts of vitamin E.
5. the composition of medicine according to claim 4 for coordinating treatment hypertension, it is characterised in that：
Including following parts by weight into subassembly：
Into subassembly E：0.38 part of vitamin A, 225 parts of vitamin C, 0.004 part of vitamin D, 2250 parts of vitamin E, dimension
Raw 5.5 parts of element B1,5.5 parts of vitamin B2,5.5 parts of vitamin B6,0.004 part of vitamin B12,0.15 part of folic acid, cigarette
12.5 parts of acid, 10 parts of pantothenic acid, 0.09 part of biotin, 300 parts of calcium, 150 parts of magnesium, 0.006 part of selenium, 0.018 part of chromium, 2 parts of manganese, copper
0.75 part, 2.15 parts of iron, 7.5 parts of zinc, 20 parts of inositol；
Into subassembly F：216.7 parts of calcium, 108.3 parts of magnesium；
Into subassembly G：1350 parts of the red sage root, 420 parts of pseudo-ginseng, 24 parts of borneol；
Into subassembly H：EPA180 parts, 120 parts of DHA, 20 parts of vitamin E.
6. the composition of medicine of the coordination treatment hypertension as described in claim 4 or 5 is coordinated treatment mild hypertension in preparation and suffered from
Application during person's medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611245849.0A CN107050107A (en) | 2016-12-29 | 2016-12-29 | A kind of composition of medicine for coordinating treatment hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611245849.0A CN107050107A (en) | 2016-12-29 | 2016-12-29 | A kind of composition of medicine for coordinating treatment hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107050107A true CN107050107A (en) | 2017-08-18 |
Family
ID=59623292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611245849.0A Pending CN107050107A (en) | 2016-12-29 | 2016-12-29 | A kind of composition of medicine for coordinating treatment hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107050107A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109380728A (en) * | 2018-10-17 | 2019-02-26 | 汤臣倍健股份有限公司 | A kind of composition and health food with auxiliary blood pressure reduction effect |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325725A (en) * | 2001-05-24 | 2001-12-12 | 魏振鸣 | Medicine for treating coronary heart disease |
| US20070292493A1 (en) * | 2006-06-15 | 2007-12-20 | Brierre Barbara T | Pharmaceutical composition and method for the transdermal delivery of calcium |
| CN102805344A (en) * | 2012-08-04 | 2012-12-05 | 东莞市照燕生物科技有限公司 | Nutrition and health product for cardia-cerebrovascular diseases |
| CN103431391A (en) * | 2013-08-28 | 2013-12-11 | 张秀平 | Comprehensive nutrition powder |
-
2016
- 2016-12-29 CN CN201611245849.0A patent/CN107050107A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325725A (en) * | 2001-05-24 | 2001-12-12 | 魏振鸣 | Medicine for treating coronary heart disease |
| US20070292493A1 (en) * | 2006-06-15 | 2007-12-20 | Brierre Barbara T | Pharmaceutical composition and method for the transdermal delivery of calcium |
| CN102805344A (en) * | 2012-08-04 | 2012-12-05 | 东莞市照燕生物科技有限公司 | Nutrition and health product for cardia-cerebrovascular diseases |
| CN103431391A (en) * | 2013-08-28 | 2013-12-11 | 张秀平 | Comprehensive nutrition powder |
Non-Patent Citations (5)
| Title |
|---|
| （美）基尔申曼: "《这样吃不生病》", 31 May 2009, 东方出版社 * |
| 任娟清: "《实用药物手册（第二版）》", 31 January 1999, 山东科学技术出版社 * |
| 刘学政等: "《全科医学概论》", 28 February 2013, 人民军医出版社 * |
| 张泽生等: "D-手性肌醇的研究与开发", 《中国食品添加剂》 * |
| 王灿等: "中药治疗高血压的研究进展", 《中国西部科技》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109380728A (en) * | 2018-10-17 | 2019-02-26 | 汤臣倍健股份有限公司 | A kind of composition and health food with auxiliary blood pressure reduction effect |
| CN109380728B (en) * | 2018-10-17 | 2022-03-22 | 汤臣倍健股份有限公司 | Composition and health food with auxiliary blood pressure lowering effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007277128A (en) | Method for prophylaxis, amelioration of lifestyle-related disease and prophylactic, ameliorant for the same | |
| CN107050107A (en) | A kind of composition of medicine for coordinating treatment hypertension | |
| CN102657828B (en) | Pharmaceutical composition for treating chronic heart failure | |
| RU2701720C1 (en) | Combinations of palmitoylethanolamide for treating chronic pain | |
| CN101361797B (en) | Traditional Chinese medicine pressure-reduction insoles | |
| JP2008120821A (en) | Use of lipase inhibitor | |
| CN103416749A (en) | Weight-losing health-care product | |
| Al-Qahtani | Surgical approaches to pediatric obesity | |
| CN102988473A (en) | Chinese medicament for treating hypertension | |
| CN105663640A (en) | Traditional Chinese medicine composition for treating chronic superficial gastritis and preparation method thereof | |
| CN104873685A (en) | Medicine for treating coronary heart disease | |
| US20130028993A1 (en) | Composition and Manufacturing Processes of a Toxicity Free Botanical Drug for Curative Treatment of Chronic Diseases | |
| CN104208318B (en) | A kind of Chinese materia medica preparation and preparation method thereof for treating apoplexy sequelae | |
| CN102526343B (en) | Traditional Chinese medicine composition for tonifying qi, activating blood and dredging collaterals | |
| CN106389949A (en) | Preparation method of traditional Chinese medicine composition for effectively alleviating lumbar pain caused by kidney deficiency | |
| Sundaravel et al. | Methylene blue to the rescue in accidental treprostinil overdose | |
| Pizzorno et al. | What is natural medicine | |
| CN105012428B (en) | A kind of Chinese medicine composition of blood pressure lowering and preparation method thereof | |
| CN104906495A (en) | Hypertension symptom improvement medicine mainly using rhodiola rosea | |
| Wang et al. | The effect of traditional Chinese medicine fumigation and washing combined with Western medical care on resting pain in elderly males with lower extremity arterial occlusion | |
| CN107261105A (en) | Treat the Chinese patent drug of cardiovascular and cerebrovascular disease | |
| CN102727775B (en) | Traditional Chinese medicine for treating gastroptosis | |
| CN112370493A (en) | Traditional Chinese medicine pill for treating ascites due to cirrhosis | |
| CN113413432A (en) | Oral Chinese medicinal composition for treating rheumatism | |
| CN109806360A (en) | A kind of Chinese medicine and its preparation method and application for treating apoplexy sequela |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |
|
| RJ01 | Rejection of invention patent application after publication |